These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 6097833)

  • 1. Differential neuropharmacological effects of mu, kappa and sigma opioid agonists on cortical EEG power spectra in the rat. Stereospecificity and naloxone antagonism.
    Young GA; Khazan N
    Neuropharmacology; 1984 Oct; 23(10):1161-5. PubMed ID: 6097833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential stereospecific effects of mu, kappa, and sigma opioid agonists on cortical EEG power spectra in the rat.
    Young GA; Khazan N
    NIDA Res Monogr; 1983 Apr; 43():190-5. PubMed ID: 6308453
    [No Abstract]   [Full Text] [Related]  

  • 3. Differential tolerance and cross-tolerance to repeated daily injections of mu and kappa opioid agonists in the rat.
    Young GA; Khazan N
    Neuropharmacology; 1984 May; 23(5):505-9. PubMed ID: 6330605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma corticosterone changes in response to central or peripheral administration of kappa and sigma opiate agonists.
    Eisenberg RM
    J Pharmacol Exp Ther; 1985 Jun; 233(3):863-9. PubMed ID: 2989500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists.
    Picker MJ; Doty P; Negus SS; Mattox SR; Dykstra LA
    J Pharmacol Exp Ther; 1990 Jul; 254(1):13-22. PubMed ID: 2164087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opiate-induced enhancement of the effects of naloxone on serum luteinizing hormone levels in the male rat: specificity for Mu agonists.
    Cicero TJ; Owens DP; Schmoeker PF; Meyer ER
    J Pharmacol Exp Ther; 1983 Sep; 226(3):770-5. PubMed ID: 6310081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Place-conditioning properties of mu, kappa, and sigma opioid agonists.
    Iwamoto ET
    Alcohol Drug Res; 1985-1986; 6(5):327-39. PubMed ID: 3011025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Similar anticonvulsant, but unique, behavioural effects of opioid agonists in the seizure-sensitive Mongolian gerbil.
    Lee RJ; Bajorek JG; Lomax P
    Neuropharmacology; 1984 May; 23(5):517-24. PubMed ID: 6330606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-allylnormetazocine (SKF-10,047): the induction of feeding by a putative sigma agonist.
    Gosnell BA; Levine AS; Morley JE
    Pharmacol Biochem Behav; 1983 Nov; 19(5):737-42. PubMed ID: 6316372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between narcotic agonists, partial agonists andd antagonists evaluated by punished an unpunished behavior in the rat.
    Snell D; Harris RA
    Psychopharmacology (Berl); 1982; 76(2):177-81. PubMed ID: 6281840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of abstinence syndromes following chronic administration of mu and kappa opioid agonists in the rat.
    Young GA; Khazan N
    Pharmacol Biochem Behav; 1985 Sep; 23(3):457-60. PubMed ID: 2996029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiating opioids by their pupillary effects in the rat.
    Robin M; Kirby A; Messner S; Geller EB; Adler MW
    Life Sci; 1985 Apr; 36(17):1669-77. PubMed ID: 2985902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sigma receptors mediated the psychotomimetic effects of N-allylnormetazocine (SKF-10,047), but not its opioid agonistic-antagonistic properties.
    Khazan N; Young GA; El-Fakany EE; Hong O; Calligaro D
    Neuropharmacology; 1984 Aug; 23(8):983-7. PubMed ID: 6090969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effects of opioid agonists and antagonists under a fixed-consecutive-number schedule in rats.
    Picker M; Heise JW; Dykstra LA
    Pharmacol Biochem Behav; 1987 May; 27(1):73-80. PubMed ID: 3615550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo.
    Kumor KM; Haertzen CA; Johnson RE; Kocher T; Jasinski D
    J Pharmacol Exp Ther; 1986 Sep; 238(3):960-8. PubMed ID: 3018228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous assessment of the opiate-induced modifications in the vertical and horizontal components of locomotor activity in mice.
    Chaillet P; Durand MA; Marçais-Collado H; Costentin J
    J Pharmacol; 1984; 15(3):375-83. PubMed ID: 6092786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sigma opioid receptors; SKF-10,047 update.
    Khazan N; Young GA; el-Fakahany EE; Hong O; Calligaro D
    Neuropeptides; 1985 Feb; 5(4-6):339-40. PubMed ID: 2987734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists.
    Picker MJ; Dykstra LA
    J Pharmacol Exp Ther; 1989 May; 249(2):557-66. PubMed ID: 2566680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concerning the specificity of the hypothalamic opiate receptor responsible for food intake in the rat.
    Tepperman FS; Hirst M
    Pharmacol Biochem Behav; 1982 Dec; 17(6):1141-4. PubMed ID: 6298827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haloperidol pretreatment unmasks the kappa opioid effects of U-50, 488H on cortical EEG and EEG power spectra in rats.
    Young GA; Marquis KL; Paquette NC; Gussio RP; Khazan N
    Neuropharmacology; 1989 Aug; 28(8):881-4. PubMed ID: 2550842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.